Novo Nordisk Operating Expenses 2010-2022 | NVO

Novo Nordisk annual/quarterly operating expenses history and growth rate from 2010 to 2022. Operating expenses can be defined as the sum of all operating expenses for the given industry.
  • Novo Nordisk operating expenses for the quarter ending June 30, 2022 were $3.271B, a 10.5% increase year-over-year.
  • Novo Nordisk operating expenses for the twelve months ending June 30, 2022 were $13.782B, a 13.11% increase year-over-year.
  • Novo Nordisk annual operating expenses for 2021 were $13.071B, a 17.17% increase from 2020.
  • Novo Nordisk annual operating expenses for 2020 were $11.156B, a 7.03% increase from 2019.
  • Novo Nordisk annual operating expenses for 2019 were $10.424B, a 5.56% increase from 2018.
Novo Nordisk Annual Operating Expenses
(Millions of US $)
2021 $13,071
2020 $11,156
2019 $10,424
2018 $9,875
2017 $9,529
2016 $9,414
2015 $8,702
2014 $9,684
2013 $9,275
2012 $8,390
2011 $8,218
2010 $7,468
2009 $6,898
Novo Nordisk Quarterly Operating Expenses
(Millions of US $)
2022-06-30 $3,271
2022-03-31 $3,451
2021-12-31 $3,829
2021-09-30 $3,231
2021-06-30 $2,960
2021-03-31 $3,051
2020-12-31 $3,328
2020-09-30 $2,845
2020-06-30 $2,388
2020-03-31 $2,596
2019-12-31 $3,049
2019-09-30 $2,586
2019-06-30 $2,498
2019-03-31 $2,291
2018-12-31 $2,562
2018-09-30 $2,488
2018-06-30 $2,434
2018-03-31 $2,391
2017-12-31 $2,825
2017-09-30 $2,302
2017-06-30 $2,256
2017-03-31 $2,146
2016-12-31 $2,669
2016-09-30 $2,268
2016-06-30 $2,273
2016-03-31 $2,204
2015-12-31 $2,614
2015-09-30 $2,208
2015-06-30 $2,160
2015-03-31 $1,720
2014-12-31 $2,618
2014-09-30 $2,435
2014-06-30 $2,370
2014-03-31 $2,261
2013-12-31 $2,610
2013-09-30 $2,223
2013-06-30 $2,242
2013-03-31 $2,200
2012-12-31 $2,330
2012-09-30 $2,014
2012-06-30 $2,042
2012-03-31 $2,004
2011-12-31 $2,148
2011-09-30 $2,095
2011-06-30 $2,091
2011-03-31 $1,884
2010-12-31 $2,072
2010-09-30 $1,829
2010-06-30 $1,798
2010-03-31 $1,770
2009-12-31 $2,055
2009-09-30 $1,677
2009-06-30 $1,630
2009-03-31 $1,536
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $236.707B $22.397B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Eli Lilly (LLY) United States $287.922B 36.51
Pfizer (PFE) United States $279.310B 8.19
AbbVie (ABBV) United States $247.976B 10.54
Merck (MRK) United States $226.779B 11.84
Novartis AG (NVS) Switzerland $192.828B 14.22